A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics is advancing CTX131, an allogeneic CAR T cell therapy targeting CD70, into a Phase 1/2 clinical trial for adult patients with relapsed/refractory hematologic malignancies. The market for CAR T therapies is expanding, particularly in hematologic cancers, with increasing demand for innovative treatments due to the limitations of existing therapies. CTX131's unique mechanism of action may provide a competitive edge in a crowded field, especially against therapies targeting CD19 and other antigens. The successful completion of this trial could position CRISPR Therapeutics favorably for regulatory approval and market entry, enhancing its portfolio in the CAR T space and potentially leading to lucrative partnerships or acquisitions.
Indication: T Cell Lymphoma
Modality: gene therapy
Target: CD70-directed chimeric antigen receptor (CAR) T cells
Sponsor: CRISPR Therapeutics
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 07, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD70-directed chimeric antigen receptor (CAR) T cells
View original source fields
Condition raw: T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
Condition normalized: T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
Modality raw: gene therapy
Modality normalized: gene therapy
Target raw: CD70-directed chimeric antigen receptor (CAR) T cells
Target normalized: CD70-directed chimeric antigen receptor (CAR) T cells